| __timestamp | Blueprint Medicines Corporation | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 11606000000 |
| Thursday, January 1, 2015 | 14456000 | 10313000000 |
| Friday, January 1, 2016 | 19218000 | 9762000000 |
| Sunday, January 1, 2017 | 27986000 | 9830000000 |
| Monday, January 1, 2018 | 47928000 | 10102000000 |
| Tuesday, January 1, 2019 | 96388000 | 10615000000 |
| Wednesday, January 1, 2020 | 157743000 | 8955000000 |
| Friday, January 1, 2021 | 195293000 | 9634000000 |
| Saturday, January 1, 2022 | 237374000 | 10042000000 |
| Sunday, January 1, 2023 | 295141000 | 10504000000 |
| Monday, January 1, 2024 | 359272000 |
Data in motion
In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Merck & Co., Inc. and Blueprint Medicines Corporation have shown contrasting trends in their SG&A expenses. From 2014 to 2023, Merck's expenses have remained relatively stable, fluctuating around $10 billion annually. In contrast, Blueprint Medicines has seen a dramatic increase, with expenses rising from approximately $8 million in 2014 to nearly $295 million in 2023, marking a staggering 3,600% increase. This divergence highlights the different growth stages and strategic priorities of these companies. While Merck focuses on maintaining its established market position, Blueprint is investing heavily in growth and expansion. Understanding these trends provides valuable insights into the operational strategies of these pharmaceutical giants.
Johnson & Johnson and Merck & Co., Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Merck & Co., Inc. vs AstraZeneca PLC Trends and Insights
Comparing SG&A Expenses: Merck & Co., Inc. vs Takeda Pharmaceutical Company Limited Trends and Insights
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and CymaBay Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Celldex Therapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Blueprint Medicines Corporation
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Axsome Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Alpine Immune Sciences, Inc.
Comparing SG&A Expenses: Blueprint Medicines Corporation vs Ligand Pharmaceuticals Incorporated Trends and Insights